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Mechanical ventilationin patients with sepsis. In 2017, we added the use of intravenous vitamin C and thiamine in septic shock patients
receiving low dose hydrocortisone because poorly responsive to vasopressors. Aim of this study is to verify
whether triple therapy rather than steroids alone can improve outcome in patients with refractory shock.Purpose: Triple therapywith steroids, vitamin C and thiamine has been recently proposed as a safe and beneficial
Materials andmethods: In this before-after retrospective analysis, we compared septic shock patients admitted to
our intensive care unit (ICU) who received triple therapy from June 2017 to November 2019 to septic shock pa-
tients who received only hydrocortisone from January 2015 to June 2017. Patients of the two study periods were
matched 1:1 using a propensity score model.
Results: A final cohort of 56 patients treated with triple therapy were matched to 56 patients treated only with
steroids. Triple therapy reduced the length of mechanical ventilation (p=0,01) and showed a trend in lowering
the 30-day and hospital mortality compared to therapy with only hydrocortisone.
Conclusions: Although with significant limitations, our experience indicated that triple therapy seems to provide
an improvement of clinical outcomes in patients with refractory septic shock.
© 2020 Published by Elsevier Inc.1. Background
Based on their pleiotropic effects at cellular andmitochondrial level,
intravenous administration of vitamin C and thiamine, combined with
steroids, has been recently promoted as a potential adjunctive therapy
in patients with septic shock [1,2]. Vitamin C is an important co-factor
for the synthesis of endogenous adrenaline and exerts multifaceted an-
tioxidant activities with a pivotal role in modulating inflammation
[1–3]. Besides, a severe deficiency of intracellular vitamin C is common
during acute illness, especially in sepsis with endotoxemia [4–6]. Thia-
mine is a key co-factor in oxidative glucose metabolism for energy pro-
duction and synthesis of glucose-derived neurotransmitters [7,8]. As
vitamin C, thiamine body reserves are also seriously reduced in critically
ill patients and, thereby, its supplementation might be reasonable, par-
ticularly in the hypermetabolic states. Moreover, thiamine modifies the
metabolism of vitamin C reducing the production of oxalate, therebyrtment of Anaesthesiology and
ozzo 71, 41125 Modena, Italy.
rdis).decreasing the likelihood of oxalate nephropathy [9,10]. Vitamin C has
been also suggested to work synergistically with hydrocortisone in
modulating inflammatory mediators, stimulating catecholamine syn-
thesis, improving endothelial function and increasing vasopressor sen-
sitivity [11–14].
In the last years, several trials indicated a possible benefit by early
administration of vitamin C in critically ill patients, particularly in pa-
tients with sepsis [15-21]. In 2014, a double-blind phase I randomized
control trial including 24 patients with severe sepsis showed that vita-
min C significantly reduced organ dysfunction and levels of pro-
inflammatory biomarkers [15]. Two years later, another randomized
controlled trial evaluated the effects of high-dose vitamin C infusion
(25 mg/kg every 6 h) in 28 surgical patients with septic shock [16].
Mean dose of vasopressors and duration of norepinephrine administra-
tion were significantly lower in vitamin C group compared to placebo.
Also, 28-day mortality, assessed as a secondary outcome, was signifi-
cantly lower among treated patients. These findings were further con-
firmed by the famous Marik's before and after study showing a
reduction in the mean duration of vasopressors and reduced in-
hospital mortality in septic patients treated with the combination of
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trials intravenous vitamin C and thiamine at dosages up to 200 mg/Kg/
day and 400mg/day, respectively, resulted to be safewithout the occur-
rence of specific adverse events.
In the second semester of 2017, on the basis of the rationale for use,
safety and possible benefit, we decided to introduce in our institutional
protocol for themanagement of septic shock intravenous vitamin C and
thiamine in patients receiving low dose hydrocortisone because poorly
responsive to vasopressors. This retrospective analysis is aimed to verify
whether adjunctive therapy with vitamin C and thiamine can improve
outcome in septic shock patients treated with steroids, as reported by
a previous similar study [17]. because of refractory septic shock.
2. Subjects and methods
2.1. Study population and treatment protocol
In this before-after case-control studywe included consecutive adult
patients admitted to the polyvalent ICU of the Modena University Hos-
pital with septic shock and receiving low-dose steroids from January
2015 to November 2019. Patients with do-not-resuscitate orders or
end of-life decisions during the ICU stay were excluded from the
study. Septic shock was diagnosed according to the Sepsis-3 definitions
[22]. Data were prospectively recorded in the electronic case report
form provided for theMargherita-PROSAFE protocol [23] and it was ap-
proved by our Area Vasta Emilia Nord Ethical Committee (17 October
-2016, 120-2016). In theMargherita-PROSAFE study protocol, the writ-
ten informed consent for data collection frompatients or their legal rep-
resentatives for their clinical records to be used in this study since
patient records/information were anonymized prior to analysis [23].
Since 2008, our institutional protocol for the management of septic
shock included the use of hydrocortisone at the dosage of 240 mg/day
in continuous intravenous infusion in patients requiring noradrenaline
dosages N0,3–0,4 μg/kg/min to maintain a mean arterial pressure
above 65 mmHg. Treatment with hydrocortisone should be started
within 12 h after shock appearance and is continued as long as patient
required vasopressor support. In June 2017, as described above, in pa-
tients receiving low dose steroids because of high vasopressor require-
ment we added in the management protocol the use of intravenous
vitamin C at the dosage of 1,5 g every 6 h and thiamine at the dosage
of 200 mg every 12 h up to discontinuation of vasoactive drugs or ste-
roids. As in the previous period, also after protocol change the high re-
quirement of vasopressors was identified with noradrenaline dosages
larger than 0,3–0,4 μg/Kg/min.
Apart vitamin C and thiamine, in the study period the overall man-
agement of patients with septic shock remained similar and in agree-
ment with the current sepsis management guidelines [24].
2.2. Data collection and analysis
Two of the authors (CI, RE), who were not involved in the direct
management of the patients, verified the data collected in the electronic
case report form collected and any uncertain data were reviewed with
the attending physician and the clinical charts. The type of admission
(medical or surgical), relevant pre-existing diseases, the primary site
of infection, the microorganisms isolated with their pattern of resis-
tance, Simplified Acute Physiology Score II (SAPS II) and Sequential
Organ Failure Assessment (SOFA) in the first 24 h after shock diagnosis
[25,26], the procalcitonin blood concentration at shock diagnosis, the
length of vasopressor administration, the length of invasive and non-
invasive mechanical ventilation, the use of other adjunctive treatments
beyondhydrocortisone, as vitamin C, thiamine and IgMpreparation, the
need for renal replacement therapy, the ICU and hospital length of stay
and the ICU and 30-day mortality rate were collected and analysed for
each patient. Infections were considered nosocomial if occurring N48 hafter hospital admission and multidrug resistant bacteria was defined
in accordance with Magiorakos et al. [27].
To verify the hypothesis of our study, we compared the patientswho
received triple therapy with low dose hydrocortisone, vitamin C and
thiamine from June 2017 to November 2019 (Treatment group) with
patients who received only hydrocortisone from January 2015 to June
2017, that is the period before protocol change (Control group). In addi-
tion, to rule out possible confounding factors, patients in the Treatment
and Control groupwerematched 1:1 by using a propensity score includ-
ing as covariates age, sex, SAPS II score, pre-existing diseases, site of in-
fection, pattern of antibiotic resistance of the isolated microorganisms,
need for mechanical ventilation and adjunctive therapy with IgM. The
30-day and hospital mortality, the length of vasoactive drug therapy
and mechanical ventilation, the need for renal replacement therapy
and the ICU length of stay were used as clinical outcome for the
comparison.
The differences in baseline characteristics and outcomes between
matched patients of the treatment and control groups were estimated
by Mann-Whitney U for continuous variables and χ2 tests for categori-
cal ones. To estimate the association between vitamin C and thiamine
adjunctive therapy and the 30-daymortality rate, univariate unadjusted
analysis andmultivariate logistic regressionwere used. Themultivariate
regression model was built including vitamin C and thiamine therapy
and variables that differed (i.e. p value b.2) in the univariate analysis.
The goodness of fit was assessed by theHosmer–Lemeshow test. All sta-
tistical tests were two-sided with p value b.05 considered significant.
SPSS version 22.0 (SPSS Inc., Chicago, IL, USA) was used to perform sta-
tistical analysis.
3. Results
In the studyperiod, 153 patientswith septic shockwere treatedwith
hydrocortisone because of high dosages of noradrenaline, 60 of which
received also with vitamin C and thiamine. After the exclusion of 21 pa-
tients with of end-of life decisions, a final cohort of 56 patients treated
with steroids (control group) and 56 treated with triple therapy (treat-
ment) werematched by the propensity scoremodel. The treatment and
control groups resulted well balanced for the co-variates considered in
thematching. Lungand gram-negative bacteriawere themost common
site of infection and micro-organisms isolated of which almost 40% re-
sulted to have a multidrug resistant pattern (Table 1). Forty-two
(75%) patients in each group received also adjunctive therapy with
IgM. Median duration of the triple therapy resulted 3 days (IQR 2–5),
with an overall median vitamin C dosage of 18 g per patient (IQR
12–30).
In the matched cohort, the 30-day and hospital mortality showed a
trend in favour of patients treated with hydrocortisone, vitamin C and
thiamine compared to patients who received only hydrocortisone (ab-
solute risk reduction 7,4% - p 0,45 and 10,7% - p 0,25, respectively)
(Fig. 1). Similarly, the length of mechanical ventilation and ICU stay
were lower in the treatment group, but only the difference in the length
of mechanical ventilation resulted to be significant (Table 1).
The unadjusted regression analysis indicated that SAPS II and SOFA
scores, medical admission and pre-existing cirrhosis were associated
with 30-day mortality; multivariate adjusted analysis demonstrated
that only SAPS II and lung as site of infection were independently re-
lated to 30-daymortality. Although not significant (p=0,11),multivar-
iate adjusted analysis showed a trend to a reduced risk of 30-day
mortality risk (OR 0,38; 95% IC 0,13-1,13) by using triple therapy
(Table 2).
4. Discussion
The results of this before-after, case-control study indicated that ad-
junctive therapy with vitamin C and thiamine in patients treated with
low dose hydrocortisone because of high dosages of noradrenaline
Table 1
Main baseline characteristics and outcomes of patients in the control (only hydrocorti-
sone) and treatment (hydrocortisone, vitamin C and Thiamine) group.
Control
group
(n = 56)
Treatment
group
(n = 56)
P value
Age (years, median-IQR) 69 (56–77) 69 (56–76) 0,731
Male (n - %) 32 (57,1) 37 (66,1) 0,331
SAPS II score (median-IQR) 56 (47–71) 61 (47–72) 0,798
SOFA score (median-IQR) 11 (8–13) 11 (8–12) 0,547
Medical admission (n - %) 33 (58,9) 36 (64,3) 0,560
Pre-existing diseases (n - %) 0,846
None 21 (37,5) 14 (25) 0,154
Heart failure 9 (16,1) 2 (3,6)
COPD 3 (5,4) 5 (8,9)
End Stage Kidney Disease 1 (1,8) 5 (8,9)
Neoplasia 13 (23,2) 12 (21,4)
Diabetes 4 (7,1) 4 (7,1)
Cirrhosis 7 (12,5) 10 (17,9)
Immunosuppression (n - %) 14 (25) 17 (30,3) 0,526
Procalcitonin (ng/dl, median- IQR) 34
(12–104)
49 (8–101)
Mechanical ventilation (n - %) 48 (85,7) 41 (73,2) 0,102
Nosocomial infection (n - %) 32 (57,1) 27 (48,2) 0,344
Site of infection (n - %) 0,696
Pulmonary 23 (41,1) 27 (48,2)
Abdominal 20 (35,7) 18 (32,1)
Bloodstream 10 (17,9) 7 (12,5)
Other 14 (25) 14 (25)
Micro-organisms (n - %) 0,530
Gram negative 40 (71,4) 37 (66,1)
Gram positive 11 (19,6) 11 (19,6)
Fungi 0 (0) 2 (3,6)
MDR 23 (41,1) 24 (42,9)
No isolates 5 (8,9) 6 (10,7)
30-day mortality (n - %) 28 (50,0) 24 (42,8) 0,449
Hospital mortality (n - %) 34 (60,7) 28 (50,0) 0,254
Vasopressors length (days, median-IQR) 4 (2–7) 3 (2–5) 0,533
Length of Mechanical ventilation (days,
median- IQR)
6 (2–15) 3 (0–8) 0,012
Renal replacement therapy (n - %) 21 (37,5) 22 (39,2) 0,846
ICU length of stay (days, median- IQR) 9 (5–15) 6 (4–10) 0,092
COPD: chronic obstructive pulmonary disease;MDR:multidrug resistant bacteria, defined
in accordance with [27]; ICU: intensive care unit.
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chanical ventilation and a trend in reducing intensive care stay and the
risk of 30 day and hospital mortality,
In the sepsis pathobiology, the combination of vitamin C, thiamine
and steroids seems to act synergistically in attenuating oxidative dam-
age, increasing glucocorticoid activity and restoring organ function
[1–17]. A recent metanalysis, including 5 small and highly heteroge-
neous studies with a total of 142 critically ill patients, showed that ad-
junctive therapy with intravenous vitamin C in patients with sepsis is
safe and seems to reduce duration of vasopressor support and me-
chanical ventilation [18]. On the same line, the recent randomized
multicentre CITRIS-ALI trial enrolling adult patients with sepsis and
acute respiratory distress syndrome showed that adjunctive treatment
with vitamin C seems to be able to improve ICU mortality and ICU free
days. Indeed, these outcomes were the secondary outcomes of the
study, whereas primary outcomes (i.e. modified SOFA scores at 96 h
and plasma biomarker levels at 168 h) did not improve with vitamin
C therapy. Noteworthy, in the trial almost 65% of the patients received
also steroids [21]. Different from the above positive results, two recent
observational trials reported no effects of adjunctive therapy with vi-
tamin C and thiamine in sepsis. A single center retrospective analysis
reported no difference in hospital mortality and other outcomes in
47 septic shock patients treated with triple therapy compared to 47
treated only with standard of care [20]. However, the two groups
could be not well matched because the decision for triple therapy
depended on the physician in charge and specific methods for limitingbiases introduced by confounding variables have not been applied.
Moreover, only 40% of the patients in the standard of care group re-
ceived steroids for refractory shock. A large before-after study with a
propensity score-based adjustment observed no improvement in sur-
vival by very early vitamin C and thiamine administration in septic
shock patients treated in emergency department [19], with a possible
benefit only in the more severe population with hypoalbuminemia
and SOFA score N 10. Noteworthy, in this study patients were treated
for only one day and many patients did not receive thiamine. More-
over, only 25% of the patients received a concomitant steroid therapy
and the reported hospital mortality of 17–18% appears to be very low
considering patients with septic shock. Similarly, the recently pub-
lished randomized trial VITAMINS, that showed no effects using com-
bination therapy with steroids, vitamin C and thiamine in patients
with septic shock admitted to ICU, reported a 28-day mortality of
20% [28]. In our study and in the study by Marik et al. [17] the hospital
mortality were at least double, ranging from 40 to 60%. This might be
partially explained by the high number of patients with severe comor-
bidities compared to the patients enrolled in VITAMINS trial [28].
The notable effects of triple therapy reported by Marik et al. [17] in
their retrospective before-after study were only partially confirmed by
our data. These discrepancies may be due to differences in patients'
characteristics and protocols between the two studies. In our study
about half of the patients had nosocomial infectionswith high incidence
of multidrug resistant pathogens whereas the population included in
theMarik et al. study had only community-acquired infections. In addi-
tion, in our study 30% of our patients had abdominal infections requiring
surgery compared to only 10% of abdominal infections reported in the
Marik el al study [17]. Similarly, also the VITAMINS trial [28] included
many patients with surgical sepsis, despite the exact number of medical
and surgical patients was not reported. Indeed, adjuvant therapy is
likely to have a lesser impact in surgical patients, where the skill of
the surgeon and the adequacy of source control are of primary impor-
tance. Another difference between the two studies is the varied delay
between shock onset and triple therapy administration that in our
trial was not initiated immediately after shock diagnosis but a few
hours later (within 12 h). As in VITAMINS trial [28], this delay might
have underpowered the effects of HAT therapy.
Our study has several limitations, mainly due to study design and
the small sample size. Although the use of propensity score model for
matching is considered an effective method in non-randomized tri-
als, the two groups appear to be well matched for baseline character-
istics and during the study period the management protocol for
septic shock patients did not change, except vitamin C and thiamine,
a selection bias in treated and controls could not be excluded in our
before-after study. The sample size of 112 patients would have
been able to detect, with a power of 80% and hospital mortality
rate of 60% in the control group, an absolute difference between
the 2 study groups in hospital mortality of about 25%, that was
lower than the difference observed in the trial from Marik et al.
that included only 94 patients [17]. Unfortunately, the difference ob-
served was only 10% and, thus, the hypothesis of beneficial effects by
vitamin C and thiamine addition to steroids could not be confirmed
by our results. Nevertheless, despite due to chance, the difference
in hospital mortality observed in our trial, associated with the low
probability of related adverse events, should be considered in the
clinical decision for an eventual adjunctive therapy with vitamin C
and thiamine, upon new evidences will be available.
In conclusion andwaiting for the future incoming trials thatwill bet-
ter define the patient who could benefit the most and the appropriate
time for administration, the rational for use combined with evidences
available so far and the results of our study, even thoughwith significant
limitations and only a trend in favour of outcomes improvement, sug-
gest that intravenous vitamin C and thiaminemay be considered a pos-
sible adjuvant therapy in patients with septic shock receiving low dose
steroids because of refractory shock.
Fig. 1.Comparison between predictedmortality (white bars) calculated by SAPS II score at admission and actualmortality rates (30-day, black bars; hospital, grey bars) in the control (only
steroids) and treatment (triple therapy) groups.
Table 2
Odds ratios and confidence interval obtained by unadjusted univariate and adjusted multivariate logistic regression analysis for 30-day mortality. Data for survived and no survived at
30 day are also reported.
Survived (n = 60) No Survived (n = 52) Unadjusted OR (95% CI); p value Adjusted ⁎ OR (95% CI); p value
Age (median; IQR) 67 (51–75) 70 (61–77) 1,02 (0,99-1,05)
0,100
1,02 (0,98-1,06)
0,381
SAPS II score (median; IQR) 48 (41–59) 70 (57–78) 1,08 (1,05-1,11)
b0,001
1,07 (1,03-1,12)
b0,001
SOFA (median; IQR) 9 (7,5–11) 12 (10–15) 1,30 (1,14-1,45)
b0,001
1,05 (0,87-1,26)
0,575
Medical admission, (n; %) 30 (50) 39 (75) 1,61 (1,15-2,24)
0,007
1,74 (0,56-4,40)
0,339
Cirrhosis (n; %) 4 (6,7) 13 (25) 2,51 (1,05-6,00)
0,007
4,07 (0,74-21,27)
0,111
Immunosuppression (n; %) 13 (21,7) 18 (34,6) 1,38 (0,88-2,18)
0,127
3,41 (0,82-14,24)
0,092
Nosocomial infection, (n; %) 28 (46,7) 31 (59,6) 1,27 (0,90-1,80)
0,171
2,31 (0,70-7,59)
0,169
Pulmonary site (n; %) 22 (36,7) 28 (53,8) 1,39 (0,96-2,02)
0,068
2,84 (0,99-8,04)
0,050
Gram negative (n; %) 46 (76,7) 31 (59,6) 0,67 (0,43-1,05)
0,052
0,44 (0,14-2,06)
0,160
Renal replacement therapy, n (%) 16 (26,7) 27 (51,9) 1,71 (1,12-2,63)
0,006
1,87 (0,64-5,65)
0,223
Vitamin C and Thiamine n (%) 32 (53,3) 24 (46,2) 0,88 (0,62-1,24)
0,449
0,38 (0,13-1,13)
0,11
⁎ Hosmer–Lemeshow goodness of fit: p= 0,78.
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